Materia Nova participated in the setting up, management and operation of the UMONS-led screening platform (SARS-CoV2 using RT-qPCR technology).

This first screening platform in Hainaut has been operational since the beginning of the epidemic for the benefit of the region's hospitals, their inpatients and their staff.

Our strengths

  • Responsiveness to requests and speed of implementation.
  • Expertise in the development of customized tests to evaluate the effectiveness of an antiviral surface treatment (SARS-CoV2...).
  • Expertise in the development of disinfection strategies (plasma on surgical masks) and adapted efficiency tests.
  • Participation in the validation of the kit based on antibodies (covid19) developed by the Mons company D-tek.

Our sectors of application for this solution

Our technologies for this solution